Balancing adjunctive therapy for tuberculosis treatment

Affiliations

¹ Department of Medicine, University of Cape Town, Cape Town 7925, South Africa; School of Public Health and Nursing, University of KwaZulu-Natal, Durban, South Africa. Electronic address: norbert.ndjeka@health.gov.za.
² Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.

Comment

Norbert Ndjeka et al. Lancet Infect Dis. 2023 Jul.

. 2023 Jul;23(7):771-772.

doi: 10.1016/S1473-3099(23)00136-6. Epub 2023 Mar 23.

¹ Department of Medicine, University of Cape Town, Cape Town 7925, South Africa; School of Public Health and Nursing, University of KwaZulu-Natal, Durban, South Africa. Electronic address: norbert.ndjeka@health.gov.za.
² Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.

No abstract available

Conflict of interest statement

We declare no competing interests.

Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.
Cross GB, Sari IP, Kityo C, Lu Q, Pokharkar Y, Moorakonda RB, Thi HN, Do Q, Dalay VB, Gutierrez E, Balanag VM, Castillo RJ, Mugerwa H, Fanusi F, Kwan P, Chew KL, Paton NI; ROSETTA trial team. Cross GB, et al. Lancet Infect Dis. 2023 Jul;23(7):847-855. doi: 10.1016/S1473-3099(23)00067-1. Epub 2023 Mar 23. Lancet Infect Dis. 2023. PMID: 36966799 Clinical Trial.